BR112015013525A2 - método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão - Google Patents
método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusãoInfo
- Publication number
- BR112015013525A2 BR112015013525A2 BR112015013525A BR112015013525A BR112015013525A2 BR 112015013525 A2 BR112015013525 A2 BR 112015013525A2 BR 112015013525 A BR112015013525 A BR 112015013525A BR 112015013525 A BR112015013525 A BR 112015013525A BR 112015013525 A2 BR112015013525 A2 BR 112015013525A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- methods
- fusion proteins
- peptides
- producing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/99—Miscellaneous (1.14.99)
- C12Y114/99003—Heme oxygenase (1.14.99.3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Abstract
abstract of the disclosure methods and systems for producing fusion proteins and peptides are disclosed. fusion proteins and peptides created using the methods are also provided. also provided are methods of using the fusion proteins and peptides produced according to the present disclosure. tradução do resumo resumo patente de invenção: "parceiros de fusão de lipocalina". métodos e sistemas para a produção de proteínas e peptídeos de fusão são descritos. proteínas e peptídeos de fusão criados usando os métodos também são fornecidos. são também fornecidos métodos de uso das proteínas e peptídeos de fusão produzidos de acordo com a presente descrição
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261735516P | 2012-12-10 | 2012-12-10 | |
US201361794685P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/074215 WO2014093403A1 (en) | 2012-12-10 | 2013-12-10 | Lipocalin fusion partners |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015013525A2 true BR112015013525A2 (pt) | 2017-11-14 |
Family
ID=49883268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013525A BR112015013525A2 (pt) | 2012-12-10 | 2013-12-10 | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão |
BR112015013515A BR112015013515A2 (pt) | 2012-12-10 | 2013-12-10 | métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015013515A BR112015013515A2 (pt) | 2012-12-10 | 2013-12-10 | métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica |
Country Status (11)
Country | Link |
---|---|
US (4) | US20140179560A1 (pt) |
EP (2) | EP2928913A1 (pt) |
JP (2) | JP2016505251A (pt) |
CN (2) | CN105189540A (pt) |
AU (2) | AU2013359429A1 (pt) |
BR (2) | BR112015013525A2 (pt) |
CA (2) | CA2913029A1 (pt) |
IL (2) | IL239262A0 (pt) |
RU (2) | RU2015126651A (pt) |
SG (2) | SG11201504600UA (pt) |
WO (2) | WO2014093406A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103097403B (zh) | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
MX349035B (es) | 2012-05-17 | 2017-07-07 | Extend Biosciences Inc | Portadores para el suministro mejorado de farmaco. |
CN105189540A (zh) | 2012-12-10 | 2015-12-23 | 弗莱德哈钦森癌症研究中心 | 含脂质运载蛋白融合伴侣 |
US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
KR101576904B1 (ko) | 2014-07-31 | 2015-12-14 | (주)케어젠 | 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도 |
WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
CN108112253B (zh) * | 2015-05-18 | 2022-09-23 | 皮里斯制药有限公司 | 抗癌融合多肽 |
CN107847554A (zh) * | 2015-06-26 | 2018-03-27 | 弗莱德哈钦森癌症研究中心 | 治疗性肽及其使用方法 |
AU2016283391A1 (en) * | 2015-06-26 | 2017-11-30 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
JP6966424B2 (ja) * | 2015-09-09 | 2021-11-17 | フレッド ハッチンソン キャンサー リサーチ センター | 軟骨ホーミングペプチド |
EP3373952A4 (en) | 2015-11-10 | 2019-05-22 | Fred Hutchinson Cancer Research Center | NKG2D decoys |
CN105348392B (zh) * | 2015-11-18 | 2019-08-02 | 北京华金瑞清生物医药技术有限公司 | 一种Nav1.7抑制剂及其改造方法 |
WO2017181149A1 (en) | 2016-04-15 | 2017-10-19 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
EP3442555A4 (en) * | 2016-04-15 | 2020-04-01 | Blaze Bioscience, Inc. | METHODS OF TREATING BREAST CANCER |
US20190292243A1 (en) * | 2016-08-22 | 2019-09-26 | Fred Hutchinson Cancer Research Center | Peptides and methods of use thereof |
US11235076B2 (en) | 2016-08-29 | 2022-02-01 | Fred Hutchinson Cancer Research Center | Chelating platform for delivery of radionuclides |
CN106699866A (zh) * | 2016-12-13 | 2017-05-24 | 山西农业大学 | 一种鸡细胞外脂肪酸结合蛋白、原核表达及其纯化方法 |
EP3571215A4 (en) | 2017-01-18 | 2020-12-30 | Fred Hutchinson Cancer Research Center | PEPTIDE COMPOSITIONS AND METHOD OF USE THEREOF TO INTERRUPT TEAD INTERACTIONS |
EP3595699A4 (en) * | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | CARTILLE HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
US11331393B2 (en) | 2017-06-15 | 2022-05-17 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
CN107739410B (zh) * | 2017-10-18 | 2021-07-30 | 南京鼓楼医院 | CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用 |
EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE |
WO2019178573A1 (en) * | 2018-03-16 | 2019-09-19 | Blaze Bioscience, Inc. | Truncated cartilage-homing peptides and peptide complexes and methods of use thereof |
AU2020407558A1 (en) * | 2019-12-19 | 2022-03-17 | Blaze Bioscience, Inc. | Methods of treating vascular lesions and malformations |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
WO1994015615A1 (en) | 1993-01-14 | 1994-07-21 | Cancer Research Campaign Technology, Ltd. | Potentiation of temozolomide in human tumour cells |
DE3407582A1 (de) | 1984-03-01 | 1985-09-05 | Dornier System Gmbh, 7990 Friedrichshafen | Schaltungsanordnung fuer einen regelkreis |
AU617652B2 (en) | 1986-09-19 | 1991-12-05 | Scripps Clinic And Research Foundation | Monoclonal paratopic molecule directed to human ganglioside gd2 |
US5591829A (en) | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
US5051364A (en) | 1989-02-16 | 1991-09-24 | The Salk Institute For Biological Studies | Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies |
DE3909799A1 (de) | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
JP2975679B2 (ja) | 1989-09-08 | 1999-11-10 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | ヒト神経膠腫のegf受容体遺伝子の構造変化 |
US5223253A (en) | 1989-09-28 | 1993-06-29 | American Home Products Corporation | Bovine vaccine compositions and method for preventing trichomonas infections using same |
US5650489A (en) * | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
GB2250993B (en) | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
HU220795B1 (hu) | 1991-09-20 | 2002-05-28 | Amgen Inc. | Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére |
US5314992A (en) | 1991-11-25 | 1994-05-24 | Trustees Of Dartmouth College | Lipocortin-1 receptor protein and its uses |
AU4373993A (en) | 1992-05-14 | 1993-12-13 | Ohio State University Research Foundation, The | Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5688773A (en) | 1994-08-17 | 1997-11-18 | The General Hospital Corporation | Method of selectively destroying neoplastic cells |
US5985822A (en) | 1994-12-09 | 1999-11-16 | The Scripps Research Institute | Inhibition of glial cell proliferation with N-CAM homophilic peptides |
US5756340A (en) | 1995-05-08 | 1998-05-26 | The Regents Of The University Of California | Insect control with multiple toxins |
JP3809502B2 (ja) | 1995-05-30 | 2006-08-16 | 二郎 有川 | ハンタウィルス抗原蛋白質およびモノクローナル抗体 |
JPH0971599A (ja) | 1995-09-06 | 1997-03-18 | Nippon Seibutsu Kagaku Kenkyusho | 鶏貧血ウイルス(cav)感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン |
US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
US6667156B2 (en) | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
WO1997043301A2 (en) * | 1996-05-10 | 1997-11-20 | Novartis Ag | Identification of members of combinatorial libraries by mass spectrometry |
US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
US6555652B1 (en) | 1997-12-05 | 2003-04-29 | Kyogo Itoh | Tumor antigen peptide derivatives |
GB9809776D0 (en) | 1998-05-07 | 1998-07-08 | Nycomed Imaging As | Method |
WO2000009502A1 (fr) | 1998-08-12 | 2000-02-24 | Daiichi Pure Chemicals Co., Ltd. | Reactifs de marquage fluorescents |
US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
DE69912444T3 (de) | 1998-08-25 | 2010-05-06 | University Of Washington, Seattle | Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US6629040B1 (en) * | 1999-03-19 | 2003-09-30 | University Of Washington | Isotope distribution encoded tags for protein identification |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6767635B1 (en) | 1999-09-14 | 2004-07-27 | Biomedical Apherese Systeme Gmbh | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use |
AUPQ339899A0 (en) * | 1999-10-13 | 1999-11-04 | University Of Queensland, The | Novel molecules |
AU4305101A (en) | 1999-11-22 | 2001-06-04 | Research Foundation Of The State University Of New York, The | Magnetic nanoparticles for selective therapy |
DE10020376A1 (de) | 2000-04-26 | 2001-11-08 | Inst Zelltechnologie E V | Dynamische Marker |
AU2002220265A1 (en) | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
US20020077921A1 (en) | 2000-12-15 | 2002-06-20 | Paul-David Morrison | Method and apparatus for an interactive catalog |
AU2002252160A1 (en) | 2001-03-01 | 2002-09-19 | Northwest Biotherapeutics, Inc. | Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
WO2003008583A2 (en) | 2001-03-02 | 2003-01-30 | Sagres Discovery | Novel compositions and methods for cancer |
GB0115581D0 (en) * | 2001-06-26 | 2001-08-15 | Glaxo Group Ltd | Method of mass spectometry |
US20030021810A1 (en) | 2001-06-26 | 2003-01-30 | Sontheimer Harald W. | Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
WO2003066663A2 (en) | 2002-02-04 | 2003-08-14 | Auburn University | Peptides for recognition and targeting of glial cell tumors |
US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
ATE458751T1 (de) | 2002-05-31 | 2010-03-15 | Transmolecular Inc | Kombinationschemotherapie mit chlorotoxin |
US20060088899A1 (en) | 2002-05-31 | 2006-04-27 | Alvarez Vernon L | Combination chemotherapy with chlorotoxin |
US7563600B2 (en) * | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
US20040101822A1 (en) | 2002-11-26 | 2004-05-27 | Ulrich Wiesner | Fluorescent silica-based nanoparticles |
WO2004085618A2 (en) | 2003-03-21 | 2004-10-07 | Schering Corporation | Method of screening for target ligands |
CN1791671A (zh) * | 2003-03-21 | 2006-06-21 | 先灵公司 | 靶配体的筛选方法 |
JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
DE10328251A1 (de) | 2003-06-24 | 2005-01-13 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
WO2005053611A2 (en) | 2003-11-26 | 2005-06-16 | Transmolecular, Inc. | Treatment of phosphatidylinositol phospholipid disorders |
DE602004020570D1 (de) * | 2003-12-18 | 2009-05-28 | Biomethodes | Verfahren zur ortspezifischen Massenmutagenese |
US20080153746A1 (en) | 2004-04-06 | 2008-06-26 | Transmolecular, Inc. | Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers |
ES2339683T3 (es) | 2004-04-06 | 2010-05-24 | Transmolecular, Inc. | Diagnostico y tratamiento de canceres de celulas mieloides y linfoides. |
CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
WO2006036928A2 (en) * | 2004-09-27 | 2006-04-06 | Wayne State University | Inhibitors of matrix metalloproteinases to treat neurological disorders |
GB0422901D0 (en) * | 2004-10-14 | 2004-11-17 | Ares Trading Sa | Lipocalin protein |
KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
GB0504767D0 (en) * | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
US7462446B2 (en) | 2005-03-18 | 2008-12-09 | University Of Washington | Magnetic nanoparticle compositions and methods |
US20070037232A1 (en) | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
WO2006110585A2 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
WO2006110582A1 (en) | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
ATE502048T1 (de) | 2005-04-22 | 2011-04-15 | Univ Washington | Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs |
KR101285904B1 (ko) | 2005-08-18 | 2013-07-15 | 암브룩스, 인코포레이티드 | tRNA 조성물 및 이의 용도 |
US20070237714A1 (en) | 2006-03-31 | 2007-10-11 | Alvarez Vernon L | Diagnosis and treatment of tumors |
US8106013B2 (en) | 2006-05-19 | 2012-01-31 | Georgia Tech Research Corporation | ABC transporter ligand GATX1 |
CN100564517C (zh) | 2006-09-21 | 2009-12-02 | 武汉大学 | 一种蝎抗神经胶质瘤肽及其制备方法和应用 |
CN101003788A (zh) | 2006-09-21 | 2007-07-25 | 武汉大学 | 一种蝎抗肿瘤转移肽及其制备方法和应用 |
AR063384A1 (es) | 2006-10-25 | 2009-01-28 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
US20090004105A1 (en) | 2007-06-27 | 2009-01-01 | Zhen Cheng | Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin |
US20110091380A1 (en) | 2007-08-07 | 2011-04-21 | Transmolecular, Inc. | Chlorotoxins as drug carriers |
US20110283260A1 (en) | 2007-08-31 | 2011-11-17 | Iosemantics, Llc | Quality assurance tools for use with source code and a semantic model |
JP2011500601A (ja) | 2007-10-12 | 2011-01-06 | トランスモレキュラー, インコーポレイテッド | 腫瘍の診断および処置のためのクロロトキシン薬剤の全身性投与 |
US20090124022A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
JP2011501673A (ja) | 2007-10-19 | 2011-01-13 | アボット・ラボラトリーズ | グリコシル化された哺乳動物ngal及びその使用 |
US20090176274A1 (en) | 2007-10-19 | 2009-07-09 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
US20090123970A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
US8846036B2 (en) | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
ES2475990T5 (es) | 2007-11-15 | 2017-07-06 | Bioporto Diagnostics A/S | Uso diagnóstico de formas moleculares individuales de un biomarcador |
WO2009092062A2 (en) | 2008-01-18 | 2009-07-23 | Visen Medical, Inc. | Fluorescent imaging agents |
WO2009108762A2 (en) | 2008-02-26 | 2009-09-03 | The Penn State Research Foundation | Methods and compositions for treatment of retinoid-responsive conditions |
US8093060B2 (en) | 2008-02-28 | 2012-01-10 | Canon Kabushiki Kaisha | Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same |
US8685370B2 (en) | 2008-03-14 | 2014-04-01 | Visen Medical, Inc. | Integrin targeting agents and in-vivo and in-vitro imaging methods using the same |
JP5586576B2 (ja) | 2008-03-20 | 2014-09-10 | トランスモレキュラー, インコーポレイテッド | 血管新生の阻害 |
GB0807831D0 (en) | 2008-04-29 | 2008-06-04 | Cambridge Entpr Ltd | Agents for imaging cell death |
CN101270158B (zh) | 2008-04-30 | 2010-12-22 | 武汉大学 | 一种靶向抗神经胶质瘤蛋白及制备方法和用途 |
EP2300045A1 (en) | 2008-05-15 | 2011-03-30 | Transmolecular, Inc. | Treatment of metastatic tumors |
JP2009300110A (ja) | 2008-06-10 | 2009-12-24 | Olympus Corp | 移植細胞の光学的検出方法又はイメージング方法 |
AU2009264214B2 (en) * | 2008-06-24 | 2013-06-06 | Technische Universitaet Muenchen | Muteins of hNGAL and related proteins with affinity for a given target |
US20100098637A1 (en) | 2008-09-23 | 2010-04-22 | The Regents Of The University Of Michigan | Dye-loaded nanoparticle |
CN101381405B (zh) | 2008-09-24 | 2011-07-27 | 武汉摩尔生物科技有限公司 | 基因工程肿瘤靶向kct-w1多肽及制备方法和用途 |
JP2010085108A (ja) | 2008-09-29 | 2010-04-15 | Nano Factory:Kk | 生体光イメージング用プローブ |
US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
US20100331650A1 (en) * | 2009-06-25 | 2010-12-30 | Roche Diagnostics Operations, Inc. | Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof |
CN106519588B (zh) | 2009-11-09 | 2019-08-20 | 华盛顿大学商业化中心 | 官能化发色聚合物点及其生物共轭体 |
CN101921769B (zh) | 2010-01-11 | 2012-07-25 | 山西大学 | 一种重组腺病毒及其制备方法和应用 |
WO2011094671A2 (en) | 2010-01-29 | 2011-08-04 | The Uab Research Foundation | N-terminally conjugated polypeptides for targeted therapy and diagnosis |
CA2788824C (en) | 2010-02-04 | 2019-03-12 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
CN101824084A (zh) | 2010-04-08 | 2010-09-08 | 山西大学 | 靶向性抗胶质瘤蛋白质及其应用 |
CN103097403B (zh) | 2010-05-11 | 2017-04-19 | 弗雷德哈钦森癌症研究中心 | 氯毒素变体、缀合物及其使用方法 |
WO2012022742A1 (en) * | 2010-08-16 | 2012-02-23 | Pieris Ag | Binding proteins for hepcidin |
US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
US10436803B2 (en) * | 2010-12-28 | 2019-10-08 | Quest Diagnostics Investments Incorporated | Quantitation of insulin by tandem mass spectrometry of insulin B chain |
EP3828271A1 (en) | 2011-09-07 | 2021-06-02 | X-Chem, Inc. | Methods for tagging dna-encoded libraries |
CN105189540A (zh) | 2012-12-10 | 2015-12-23 | 弗莱德哈钦森癌症研究中心 | 含脂质运载蛋白融合伴侣 |
-
2013
- 2013-12-10 CN CN201380072523.0A patent/CN105189540A/zh active Pending
- 2013-12-10 WO PCT/US2013/074218 patent/WO2014093406A1/en active Application Filing
- 2013-12-10 US US14/102,396 patent/US20140179560A1/en not_active Abandoned
- 2013-12-10 AU AU2013359429A patent/AU2013359429A1/en not_active Abandoned
- 2013-12-10 AU AU2013359426A patent/AU2013359426A1/en not_active Abandoned
- 2013-12-10 JP JP2015545938A patent/JP2016505251A/ja active Pending
- 2013-12-10 CN CN201380072527.9A patent/CN105008393A/zh active Pending
- 2013-12-10 JP JP2015545941A patent/JP2016505826A/ja not_active Ceased
- 2013-12-10 US US14/651,172 patent/US20150316536A1/en not_active Abandoned
- 2013-12-10 WO PCT/US2013/074215 patent/WO2014093403A1/en active Application Filing
- 2013-12-10 BR BR112015013525A patent/BR112015013525A2/pt not_active IP Right Cessation
- 2013-12-10 SG SG11201504600UA patent/SG11201504600UA/en unknown
- 2013-12-10 US US14/651,175 patent/US10156559B2/en active Active
- 2013-12-10 EP EP13814341.7A patent/EP2928913A1/en not_active Withdrawn
- 2013-12-10 RU RU2015126651A patent/RU2015126651A/ru not_active Application Discontinuation
- 2013-12-10 CA CA2913029A patent/CA2913029A1/en not_active Abandoned
- 2013-12-10 SG SG11201504602VA patent/SG11201504602VA/en unknown
- 2013-12-10 CA CA2913127A patent/CA2913127A1/en not_active Abandoned
- 2013-12-10 BR BR112015013515A patent/BR112015013515A2/pt not_active IP Right Cessation
- 2013-12-10 EP EP13814726.9A patent/EP2928914A1/en not_active Withdrawn
- 2013-12-10 RU RU2015126650A patent/RU2015126650A/ru not_active Application Discontinuation
-
2015
- 2015-06-07 IL IL239262A patent/IL239262A0/en unknown
- 2015-06-07 IL IL239261A patent/IL239261A0/en unknown
-
2018
- 2018-12-11 US US16/216,625 patent/US20190101528A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2013359426A1 (en) | 2015-07-09 |
CN105189540A (zh) | 2015-12-23 |
JP2016505826A (ja) | 2016-02-25 |
US20150322123A1 (en) | 2015-11-12 |
BR112015013515A2 (pt) | 2017-11-14 |
IL239262A0 (en) | 2015-07-30 |
JP2016505251A (ja) | 2016-02-25 |
US20150316536A1 (en) | 2015-11-05 |
US20190101528A1 (en) | 2019-04-04 |
US20140179560A1 (en) | 2014-06-26 |
AU2013359429A2 (en) | 2015-11-12 |
AU2013359426A2 (en) | 2015-11-05 |
US10156559B2 (en) | 2018-12-18 |
EP2928914A1 (en) | 2015-10-14 |
RU2015126650A (ru) | 2017-01-12 |
AU2013359429A1 (en) | 2015-07-09 |
RU2015126651A (ru) | 2017-01-16 |
IL239261A0 (en) | 2015-07-30 |
CA2913029A1 (en) | 2014-06-19 |
WO2014093406A1 (en) | 2014-06-19 |
WO2014093403A1 (en) | 2014-06-19 |
CN105008393A (zh) | 2015-10-28 |
CA2913127A1 (en) | 2014-06-19 |
SG11201504602VA (en) | 2015-07-30 |
SG11201504600UA (en) | 2015-07-30 |
EP2928913A1 (en) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
PE20150645A1 (es) | Proteinas de fusion de interleuquina 10 y usos de las mismas | |
BR112017018975A2 (pt) | proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas | |
BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
BR112015022208A8 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
BR112015011389A2 (pt) | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica | |
WO2013151666A3 (en) | Modified polynucleotides for the production of biologics and proteins associated with human disease | |
AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
BR112014018630A2 (pt) | alvejamento de glicanos de sulfato de condroitina | |
AU2012257942A8 (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
EP3674320A3 (en) | Production of heterodimeric proteins | |
TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
BR112014015933A2 (pt) | métodos e materiais para reduzir a degradação das proteínas recombinantes | |
PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
BR112015021993A2 (pt) | composições de cultura celular com antioxidantes e métodos para produção de polipeptídeo | |
EA201491784A1 (ru) | Антитела против лигандов рецептора в1 брадикинина | |
BR112016006606A2 (pt) | Molécula de ácido nucléico recombinante, molécula de aminoácido recombinante, construção de expressão recombinante, vetor recombinante, micro-organismo recombinante, composição, método de produção de aminoácidos, uso de uma molécula de ácido nucléico e processo de produção fermentativa | |
BR112013004124A2 (pt) | peptídeo ou complexo de peptídeos ligando a alfa2 integrina e métodos e utilizações envolvendo os mesmos | |
WO2012054929A3 (en) | Use of human serum albumin to decrease antigenicity of therapeutic proteins | |
BR112015021785A2 (pt) | Promotores de levedura para expressão de proteína | |
AR092879A1 (es) | Proteinas de fusion de g3p como agentes de union a amiloide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |